![Joseph Felder](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Joseph Felder
Nessuna posizione attualmente
Profilo
Joseph Felder was a Co-Chairman at Crohn's & Colitis Foundation of America.
He was also a Director at Ventrus Biosciences, Inc. from 2008 to 2011.
He holds a doctorate degree from The University of Texas at Austin and another doctorate degree from the University of Texas at San Antonio, which was conferred in 1987.
Precedenti posizioni note di Joseph Felder
Società | Posizione | Fine |
---|---|---|
Crohn's & Colitis Foundation of America
![]() Crohn's & Colitis Foundation of America Miscellaneous Commercial ServicesCommercial Services Crohn's & Colitis Foundation of America is a non-profit organization that is run by volunteers. The non-profit company is based in New York, NY and has subsidiaries in the United States. The organization is dedicated to finding cures for Crohn's disease and ulcerative colitis, and improving the quality of life of children and adults affected by these diseases. The CEO of the company is Richard J. Geswell. | Presidente | - |
Ventrus Biosciences, Inc.
![]() Ventrus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ventrus Biosciences, Inc. is a development stage specialty pharmaceutical company engages in development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoidal disease, anal fissures, and fecal incontinence. Its major pharmaceutical progress made in the gastrointestinal therapeutic areas of gastroesophageal reflux, peptic ulcer disease, and inflammatory bowel disease. Ventrus Biosciences products includes VEN 307 (topical diltiazem), is intended to treat pain associated with anal fissures and VEN 308 (topical phenylephrine), is intended to treat fecal incontinence. The company was founded on October 10, 2005 and is headquartered in New York, NY. | Direttore/Membro del Consiglio | - |
Formazione di Joseph Felder
The University of Texas at Austin | Doctorate Degree |
University of Texas at San Antonio | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
Ventrus Biosciences, Inc.
![]() Ventrus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Ventrus Biosciences, Inc. is a development stage specialty pharmaceutical company engages in development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoidal disease, anal fissures, and fecal incontinence. Its major pharmaceutical progress made in the gastrointestinal therapeutic areas of gastroesophageal reflux, peptic ulcer disease, and inflammatory bowel disease. Ventrus Biosciences products includes VEN 307 (topical diltiazem), is intended to treat pain associated with anal fissures and VEN 308 (topical phenylephrine), is intended to treat fecal incontinence. The company was founded on October 10, 2005 and is headquartered in New York, NY. | Health Technology |
Crohn's & Colitis Foundation of America
![]() Crohn's & Colitis Foundation of America Miscellaneous Commercial ServicesCommercial Services Crohn's & Colitis Foundation of America is a non-profit organization that is run by volunteers. The non-profit company is based in New York, NY and has subsidiaries in the United States. The organization is dedicated to finding cures for Crohn's disease and ulcerative colitis, and improving the quality of life of children and adults affected by these diseases. The CEO of the company is Richard J. Geswell. | Commercial Services |
- Borsa valori
- Insiders
- Joseph Felder